Clinical Evaluation of RFAL of Breast Envelope and NAC Position

Inclusion Criteria: * Informed consent agreement signed by the subject. * Healthy females 21 to 60 years of age. * Presence of grade I-III Breast Ptosis, mastopexy with history of breast augmentation, correction of asymmetry, mastopexy alone, mastopexy following implant removal and modest breast reduction in combination with or without lipoaspiration. * Post-menopausal or surgically sterilized or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study (i.e., oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide, or abstinence). * Willingness to follow the treatment and follow-up schedule and the post-treatment care. * All participants must have a recorded mammogram before the beginning of the study. Exclusion Criteria: * Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body. * Permanent implant in the treated area such as metal plates and screws, silicone implants or an injected chemical substance. * Current or history of skin cancer (remission of 5 years), or current condition of any other type of cancer, or pre-malignant moles. * Severe concurrent conditions, such as cardiac disorders, epilepsy, uncontrolled hypertension, and liver or kidney diseases. * History of bleeding coagulopathies or use of anticoagulants in the last 2 weeks. * Impaired immune system due to immunosuppressive diseases such as AIDS and HIV or use of immunosuppressive medications. * Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction. * Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash. * History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin. * Use of Isotretinoin (Accutane®) within 6 months prior to treatment. * Significant systemic illness or occult systemic illness. * Illness, infection or skin diseases localized in area of treatment. * Other therapies or medication which may interfere with treatment. * Breastfeeding, pregnant, or planning to become pregnant during the study. * Allergy to lidocaine or other anaesthesia. * Recent surgery in treatment area within the past 6 months. * Participation in a study of another device or drug within 3 months prior to enrolment or during this study. * As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the patient to participate in this study. * As per the practitioner's discretion, refrain from treating any condition that might make it unsafe for the patient.